MarginsXMarginsX
Home › Markets › Health Care › EVAX

Evaxion A/S American Depositary Share (EVAX)

EVAX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.77
+0.54% on the day
Market cap
$25.5M
Nano cap
Revenue · 2025
$7.5M
+125.1% on 2024
Net income · 2025
-$7.7M
-102.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/0001171843-26-001346-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerEVAX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryDenmark
IPO year2021
SEC CIK0001828253
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDenmark

Financials · 2025

LineValue
Revenue$7.5M
Net income-$7.7M
Operating income-$9.2M
Net margin-102.4%
Operating margin-122.7%
Revenue growth+125.1%
Cash$23.2M
Total assets$28.4M
P/E (computed)Net income was not positive
P/S (computed)3.4×

Warning signs

Cash runway
42.1 months
$23.2M cash at December 31, 2025
Share count, 1 year
+494.6%
2024-12-31 to 2025-12-31 · +1627.5% over 3 years
Going-concern doubt
No
20-F filed March 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-05
Cash and burn$23.2M cash; operating cash flow -$1.7M a quarter.Report 2025-12-31
Shares outstanding8,340,215 (2025-12-31); 1,402,611 a year earlier; 482,788 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2025-12-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEY Godkendt Revisionspartnerselskab, Copenhagen, DenmarkPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$7.5M-$7.7M-$6.6M$23.2M$5.5M$7.5M20-F 2026-03-05
FY 2024
2024-12-31
$3.3M-$10.6M-$12.9M$6.0M$8.2M$3.3M20-F 2026-03-05
FY 2023
2023-12-31
$73K-$22.1M-$17.7M$5.6M$8.6M$73K20-F 2026-03-05
FY 2022
2022-12-31
$0-$23.2M-$25.8M$13.2M$8.0M$020-F 2025-04-01
FY 2021
2021-12-31
Not filed-$24.5M-$21.9M$32.2M$1.2MNeeds four quarters20-F 2024-03-26
FY 2020
2020-12-31
Not filed-$15.0M-$12.4M$5.8MNo debt tagsNeeds four quarters20-F 2023-04-28
FY 2019
2019-12-31
Not filed-$11.2M-$7.0M$9.6MNo debt tagsNeeds four quarters20-F 2022-03-31
FY 2018
2018-12-31
Not filed-$5.5M-$2.0M$7.4M$8.6MNeeds four quarters20-F 2021-04-07

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B3
424B32026-11-13
Latest annual report
FORM 20-F
20-F2026-03-05
Latest quarterly / interim
FORM 6-K
6-K2026-11-12

Source: SEC EDGAR submissions feed, 370 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.7%
1 month-0.7%
3 months-14.7%
Year to date-42.6%
1 year-52.0%
From 52-week high-58.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
MGXMetagenomi Therapeutics Inc.$0.6800-1.69%$25.7M
PTHSPelthos Therapeutics Inc.$7.15-3.90%$28.1M
SAENGenenta Science S.p.A.$0.6000-7.66%$28.9M
CVMCel-Sci Corporation$1.66+29.69%$29.2M
INMBINmune Bio Inc.$0.9464-9.87%$29.3M
LONALeonaBio Inc.$3.23-6.92%$30.4M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
BSEMBioStem Technologies Inc.$0.9601-8.56%$18.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier